Who founded Signatur Biosciences?

Signatur Biosciences was founded by John Goertz, Celestin de Wergifosse, Celestin de Wergifiosse in 2022.

Who are Signatur Biosciences's investors?

Signatur Biosciences's investors include Anjost, Myelin VC, Riceberg Ventures Premier, Y Combinator, Asymmetry Ventures, Meusinvest (Noshaq), Roundtable Elyos Energy, Special, Stanford University.

Where is Signatur Biosciences headquartered?

Signatur Biosciences is headquartered in London, GB.

Signatur Biosciences

YC S22

London, GB · Founded 2022 · 5 employees · 10 known investors

Find your way into Signatur Biosciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Signatur Biosciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.

Biotech Digital Health Healthtech Medical Devices Healthcare DiagnosticsUnited KingdomEuropePartly Remote

Founders & leadership· Y Combinator alumni (S22)

Signatur Biosciences was founded in 2022 by John Goertz, Celestin de Wergifosse, and Celestin de Wergifiosse.

John Goertz Co-founder · Chief Scientific Officer2022–2025John Goertz is co-founder and chief scientific officer at Signatur Biosciences, where he applies machine learning to PCR-based diagnostics. He completed postdoctoral research at Imperial College London's Stevens Group as an NIH F32 fellow, and holds a PhD in bioengineering from the University of Maryland, College Park and a BSc in physics and cell & molecular biology from Seattle University.

Celestin de Wergifosse Co-founder and CEOHe studied bio-engineering at Imperial College London and has founded multiple ventures including Young Change Maker and Sauna en Bois, the latter of which he sold.

Celestin de WergifiosseCEO

Board

Prof Dame Molly Stevens Scientific Advisory Board Chair, Co-inventorNon-Executive Director at Oxford Science Enterprises

Investors · 10

Anjostlisted by AnjostOxford

How we know: Anjost's portfolio page · Y Combinator's founder network · Not right? Tell us

Myelin VClisted by Myelin VCMontevideo · $250K – $1M

How we know: Myelin VC's portfolio page · Not right? Tell us

Riceberg Ventures Premierlisted by Riceberg Ventures PremierAdliswil

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Asymmetry VenturesreportedRichmond · $125K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

Meusinvest (Noshaq)reportedLiege

How we know: Y Combinator's founder network · Not right? Tell us

Roundtable Elyos Energy, SpecialreportedLuxembourg

How we know: Y Combinator's founder network · Not right? Tell us

Stanford UniversityreportedStanford

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 2

NoshaqThe Discovery Lab of IBAlead

Funding

SEC filings, press & company announcements

Undisclosed amountSeed roundMay 2019
The Discovery Lab of IBA (lead), Noshaq
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 6

Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

NumenNumen develops at-home cancer diagnostics and health data collection infrastructure using machine learning models to enable earlier intervention and improve patient outcomes.

AminoAnalyticaAmino Analytica designs rapid molecular diagnostic tests for emerging infectious diseases and biological threats, developed in weeks rather than the traditional 12+ months. The company combines point-of-care diagnostics technology with AI-driven bionanotechnology to enable earlier detection and faster pandemic response.

BiocartesianBiocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.

Pando BiosciencePando develops enzyme design and optimization using machine learning to accelerate the design-build-test-learn cycle for biotechnology applications.

Yemaachi BiotechnologyYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.

Companies working in the same space as Signatur Biosciences.

Legal entities · 1

corporate structure

Signatur Biosciences, Inc.

Companies House · registry record

View on Companies House ↗

Registered name: SIGNATUR BIOSCIENCES LTD
Company number: 14027651
Status: Active
Company type: Private limited company
Incorporated: 5 Apr 2022
Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ
Nature of business (SIC): 71122 — Engineering related scientific and technical consulting activities
Accounts: last made up to 30 Apr 2025 · next due 31 Jan 2027
Confirmation statement: last made up to 4 Apr 2026 · next due 18 Apr 2027

Current officers · 1

Celestin De Wergifosse — director, appointed 5 Apr 2022

Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

🧪 Signatur Biosciences diagnoses anything with a simple PCR test.ycombinator.com · Jul 2022

Signatur Biosciences Raises $7M to Make Breast Cancer Prognostic Testing Accessible Everywhere — SIGNATUR BIOsignatur.bio · May 2019

Frequently asked questions

What does Signatur Biosciences do?: Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.
Who founded Signatur Biosciences?: Signatur Biosciences was founded by John Goertz, Celestin de Wergifosse, Celestin de Wergifiosse in 2022.
Who are Signatur Biosciences's investors?: Signatur Biosciences's investors include Anjost, Myelin VC, Riceberg Ventures Premier, Y Combinator, Asymmetry Ventures, Meusinvest (Noshaq), Roundtable Elyos Energy, Special, Stanford University.
Where is Signatur Biosciences headquartered?: Signatur Biosciences is headquartered in London, GB.